TuHURA Biosciences Enters Material Definitive Agreement
Ticker: HURA · Form: 8-K · Filed: Oct 31, 2025 · CIK: 1498382
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
TuHURA Bio just signed a big deal, creating new financial obligations. Keep an eye on this.
AI Summary
TuHURA Biosciences, Inc. announced on October 27, 2025, that it entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The company, formerly known as Kintara Therapeutics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector.
Why It Matters
This filing signals a significant new agreement for TuHURA Biosciences, potentially impacting its financial obligations and future operations.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks and uncertainties for a company.
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- October 27, 2025 (date) — Date of earliest event reported
- Kintara Therapeutics, Inc. (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
FAQ
What is the nature of the material definitive agreement entered into by TuHURA Biosciences?
The filing indicates the entry into a material definitive agreement but does not specify its nature in the provided text.
What type of financial obligation has TuHURA Biosciences created?
The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the specifics are not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 27, 2025.
What was TuHURA Biosciences' former company name?
TuHURA Biosciences, Inc. was formerly known as Kintara Therapeutics, Inc.
In which state is TuHURA Biosciences incorporated?
TuHURA Biosciences, Inc. is incorporated in Nevada.
Filing Stats: 883 words · 4 min read · ~3 pages · Grade level 11.9 · Accepted 2025-10-31 17:00:27
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
- $3,000,000 — an aggregate principal amount of up to $3,000,000 (the "Loans") during a 30-day availabil
- $1,500,000 — st loan to the Company in the amount of $1,500,000 simultaneously with the execution of th
- $12,000,000 — ceives gross cash proceeds in excess of $12,000,000. The outstanding principal amount of th
- $180,000 — The Loan Agreement also provides for a $180,000 loan fee payable to the Lender on the m
Filing Documents
- hura-20251027.htm (8-K) — 54KB
- hura-ex10_1.htm (EX-10.1) — 154KB
- hura-ex10_2.htm (EX-10.2) — 178KB
- img194250664_0.jpg (GRAPHIC) — 291KB
- 0001193125-25-260924.txt ( ) — 948KB
- hura-20251027.xsd (EX-101.SCH) — 30KB
- hura-20251027_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. Bridge Loan Transaction On October 27, 2025, TuHURA Biosciences, Inc. (the "Company") entered into a Secured Promissory Note and Loan Agreement (the "Loan Agreement") with the Matthew Nachtrab Revocable Trust dated 12/18/2014 (the "Lender"). Pursuant to the terms of the Loan Agreement, the Lender agreed to make loans to the Company in an aggregate principal amount of up to $3,000,000 (the "Loans") during a 30-day availability period beginning on the date of the Loan Agreement. The Lender advanced the first loan to the Company in the amount of $1,500,000 simultaneously with the execution of the Loan Agreement (the "Initial Advance"), and upon advance notice by the Company in accordance with the terms therein, may loan up to an additional $1,500,000. The Loans will be used by the Company for working capital purposes. The outstanding principal, plus any accrued and unpaid interest, of the Loans will be due and payable on the earlier of December 31, 2025 or on the date that is 30 days following the successful closing of an equity financing in which the Company receives gross cash proceeds in excess of $12,000,000. The outstanding principal amount of the Loans will bear an interest rate of 3% per month, payable in arrears on the maturity date. The Company may prepay all or a portion of the outstanding principal and accrued but unpaid interest under the Loan Agreement at any time without a prepayment fee. The Loan Agreement also provides for a $180,000 loan fee payable to the Lender on the maturity date. The Loan Agreement provides for customary representations, warranties and covenants made by each the Company and the Lender. The Loan Agreement is secured by a first priority perfected security interest in U.S patents owned by the Company related to its ImmuneFx TM technology platform. In addition, in connection with each loan advance made pursuant to the Loan Agreement, the Company will issue to the Lender a
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No 10.1 Secured Promissory Note and Loan Agreement 10.2 Form of Lender Warrant 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: October 31, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer